ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

18th European Diabetes Congress
July 17-18, 2017|Lisbon, Portugal

Sherry Elisha Mata, Nehal Hamdy El-Said, Noha Adly Sadik and Nagwa Abd El-Ghaffar Mohamed
Cairo University, Egypt
National Research Center, Egypt
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156-C1-066
Adipose tissue has been known as a source of a variety of bioactive peptides called adipokines. Recently, a new protein omentin-1 (also named intelectin-1, endothelial lectin and intestinal lactoferrin receptor) has been identified as a major visceral (omental) fat secretory adipokine. Omentin is highly and selectively expressed in visceral adipose tissue relative to subcutaneous adipose tissue and together with visceral obesity play important roles in carbohydrate and lipid metabolism, homeostasis, insulin resistance, diabetes and cardiovascular function. Insulin resistance links nutrition, glucose, insulin and adipokines in various metabolic important tissues. While, omentin is highly expressed in human visceral fat tissue, circulating omentin levels are reduced in obese subjects. Omentin is also down-regulated in association with obesity- linked metabolic disorders including insulin resistance, glucose intolerance and type 2 diabetes. The aim from our study was to increase our knowledge about omentin-1 and its relationship with type 2 diabetes mellitus, insulin resistance and obesity. The study included 60 female patients with type 2 diabetes mellitus with their age group (40-60). 30 aged matched female subjects formed the control group. All subjects were subjected to full clinical examination, body weight, height, BMI, waist and hip circumference, fasting plasma glucose, fasting insulin, fasting serum lipid profile, HbA1c and fasting omentin-1 levels. Insulin resistance was calculated as HOMA-IR. We found the serum Omentin-1 significantly lower in cases as compared to control group (p value<0.001). We also found that plasma omentin-1 is inversely related to obesity (negatively correlated to BMI, weight, waist and hip circumference). A statistically significant positive correlation between weight, BMI, waist, hip circumference, fasting glucose, HbA1c, insulin and insulin resistance within cases were detected in our study. In our study, the ROC curve analysis showed that the cutoff value of serum omentin-1 levels was 22.2 pg/mL (yielding sensitivity and specificity values of 100% for both). These results emphasize the usefulness of the discriminant ability of plasma omentin -1 to differentiate between cases (who were obese and having high insulin resistance) and controls. Our study showed that omentin-1 levels are low in type 2 diabetic and insulin resistant females. We also found that plasma omentin-1 is inversely related to obesity (BMI, weight, waist and hip circumference).

Sherry Elisha Mata has completed her Master’s degree from Cairo University, Egypt. Currently, she is doing her PhD at the Cairo University, Egypt and Postgraduate Diploma in Diabetes from Cardiff University, England.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version